Health and Healthcare

How Analysts Value Gilead Now After Earnings

Thinkstock

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter financial results on Tuesday. As a result, analysts weighed in on this biotech giant and in what direction it might go next.

The company had $3.32 in earnings per share (EPS) on $8.51 billion in revenue, versus Thomson Reuters consensus estimates that called for $3.00 in EPS on revenue of $8.13 billion. The same period from the previous year had EPS of $2.43 on $7.31 billion in revenue.

In the fourth quarter of 2015, product sales in the United States were $4.8 billion, compared to $5.5 billion in the fourth quarter of 2014. In Europe, product sales were $1.7 billion, compared to $1.4 billion a year ago. Sales in other international locations increased to $1.9 billion, compared to $373 million.

Harvoni sales totaled $3.35 billion in the fourth quarter, compared to $2.11 billion last year. Sovaldi sales totaled $1.55 billion this year, which came down from $1.73 billion.

As for full-year 2016 guidance, Gilead expects to have net product sales in the range of $30 billion to $31 billion, compared to the consensus estimate of $31.68 billion in revenue.


A few analysts poured into Gilead following the release of its earnings report:
  • Barclays kept its Overweight rating but lowered its price target to $115 from $130.
  • Merrill Lynch has a Neutral rating and lowered its price target from $107 to $104.
  • Goldman Sachs kept a Neutral rating but lowered its price target to $91 from $100.
  • JPMorgan maintained its Overweight rating but lowered its target price to $122 from $133.
  • Morgan Stanley kept an Equal Weight rating but lowered its price target from $120 to $111.
  • RBC Capital Markets kept an Outperform rating but lowered its price target to $120 from $130.

Shares of Gilead closed Friday at $85.14, with a consensus analyst price target of $118.28 and a 52-week trading range of $81.89 to $123.37.

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.